Patient-Reported Outcomes After 52 Weeks of Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab

Conference Reports for NATAP

Conference on Retroviruses
and Opportunistic Infections
Denver, CO 80202, United States
February 22 - 25, 2026